Hidradenitis Suppurativa (HS) Completed Phase 1 Trials for Efalizumab (DB00095)

Also known as: Hidradenitis Suppurativa / Hidradenitis / Sweat gland inflammation / Acne inversa

IndicationStatusPhase
DBCOND0054533 (Hidradenitis Suppurativa (HS))Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00134134Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis SuppurativaTreatment